ReviewFrontiers in cell and developmental biology2025
Tumor suppressor function of formyl peptide receptor 1 in gastrointestinal cancers: a focus on the underlying signaling.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The homeostasis of a tissue such the gastrointestinal (GI) tract is of fundamental importance for human health, given its constant exposure to a wide variety of external substances. The Formyl peptide Receptor 1 (FPR1) is an innate immune receptor belonging to the FPR family, that can recognize various endogenous danger- and exogenous pathogen-associated molecules, triggering inflammation. Importantly, depending on the context and on the specific ligand, FPR1 can also stimulate inflammation resolution. Thus, FPR1 is a critical actor in GI physiopathology. Interestingly, not only FPR1 participates and is necessary for maintaining homeostasis, but it also exerts strong tumor suppressor properties in this tissue. The present review discusses the mechanisms responsible for this specific function of FPR1 in cancer of the GI tract, focusing in particular on FPR1-mediated signal transduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.